DHH-B (Dihydrohonokiol-B)
Synthetic peptide studied in animal and cell models for selective anxiolytic activity and stress-metabolism axis research
Last updated: March 1, 2026
- Compound
- DHH-B (Dihydrohonokiol-B)
- Class
- Body Composition peptide
- Summary
- Synthetic peptide studied in animal and cell models for selective anxiolytic activity, stress-metabolism axis research, antioxidant and cytoprotective properties.
- Mechanism
- Cytoprotective & Antioxidant Activation
- Research Status
- Preclinical
- Routes Studied
- Oral administration (capsule)
- Evidence Level
- Preclinical-promising · Clinically unproven
What Should You Know About DHH-B (Dihydrohonokiol-B)?
- What is DHH-B (Dihydrohonokiol-B)?
- DHH-B (Dihydrohonokiol-B) is a synthetic peptide studied in animal and cell models for selective anxiolytic activity and stress-metabolism axis research.
- Is DHH-B (Dihydrohonokiol-B) clinically proven?
- No. Human evidence remains limited and does not establish DHH-B (Dihydrohonokiol-B) as clinically proven.
- What has DHH-B (Dihydrohonokiol-B) been studied for?
- DHH-B (Dihydrohonokiol-B) has been studied in preclinical models of selective anxiolytic activity, stress-metabolism axis research, antioxidant and cytoprotective properties. These findings have not been confirmed in large-scale human trials.
- Is DHH-B (Dihydrohonokiol-B) approved?
- No. DHH-B (Dihydrohonokiol-B) is not an approved drug and remains a research compound.
What Is DHH-B (Dihydrohonokiol-B)?
Dihydrohonokiol-B (DHH-B) is a synthetic bioactive derivative of honokiol, a biphenolic neolignan naturally occurring in the bark of Magnolia officinalis and Magnolia obovata, trees used for centuries in traditional East Asian medicine. While honokiol itself has been extensively researched for its anxiolytic, anti-inflammatory, and neuroprotective properties, DHH-B represents a semi-synthetic modification designed to enhance selectivity for specific molecular targets, particularly the gamma-aminobutyric acid type A (GABA-A) receptor complex. DHH-B is...
Evidence Summary
DHH-B (Dihydrohonokiol-B) has preliminary preclinical evidence only. Human clinical trial data is not available.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Selective Anxiolytic Activity | Insufficient |
| Stress-Metabolism Axis Research | Insufficient |
| Antioxidant and Cytoprotective Properties | Insufficient |
| Oral Bioavailability and CNS Penetration | Insufficient |
| Human clinical evidence | Limited |
| Safety data | Insufficient |
Editorial Position
DHH-B (Dihydrohonokiol-B) is best understood as a preclinical research compound with promising biological signals but limited human validation. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Not approved as a therapeutic drug by major regulators
- Safety profile not established in large human populations
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for DHH-B (Dihydrohonokiol-B) is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has DHH-B (Dihydrohonokiol-B) Been Studied For?
Research areas where DHH-B (Dihydrohonokiol-B) has been investigated in published studies
-
Selective Anxiolytic Activity DHH-B (Dihydrohonokiol-B) has been studied in animal models of selective anxiolytic activity. These findings have not been confirmed in controlled human trials.
-
Stress-Metabolism Axis Research DHH-B (Dihydrohonokiol-B) has been studied in animal models of stress-metabolism axis research. These findings have not been confirmed in controlled human trials.
-
Antioxidant and Cytoprotective Properties DHH-B (Dihydrohonokiol-B) has been studied in animal models of antioxidant and cytoprotective properties. These findings have not been confirmed in controlled human trials.
-
Oral Bioavailability and CNS Penetration DHH-B (Dihydrohonokiol-B) has been studied in animal models of oral bioavailability and cns penetration. These findings have not been confirmed in controlled human trials.
How Does DHH-B (Dihydrohonokiol-B) Work?
These mechanisms have been observed in preclinical models. They are plausible but have not been linked to proven clinical outcomes in humans.
- 01 GABA-A Receptor Allosteric Binding
- 02 Selective GABAergic Potentiation
- 03 HPA Axis Modulation
- 04 Cortisol-Mediated Metabolic Pathway Influence
Not sure if DHH-B (Dihydrohonokiol-B) is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about DHH-B (Dihydrohonokiol-B).
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate DHH-B (Dihydrohonokiol-B)
How Is DHH-B (Dihydrohonokiol-B) Administered?
DHH-B (Dihydrohonokiol-B) is available via Oral administration (capsule). Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of DHH-B (Dihydrohonokiol-B)?
What Conditions Has DHH-B (Dihydrohonokiol-B) Been Linked To?
Have Questions About DHH-B (Dihydrohonokiol-B)?
DHH-B's relevance to body composition research stems from its effects on the stress-cortisol-metabolism axis. Chronic stress and elevated cortisol are associated with increased visceral adiposity and metabolic dysfunction.
Published studies on DHH-B (Dihydrohonokiol-B) can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
DHH-B (Dihydrohonokiol-B) is available as a research compound in Thailand. Consult a qualified specialist to discuss whether it is appropriate for your needs.
Ready to discuss DHH-B (Dihydrohonokiol-B) with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026